Press Release: BiovaxID

[Guest guest]

SinuNase interim, blinded data for CS (Graphic: Business Wire) (3º)

07/01/2008 14:00:00 Business Wire US0303711081 expected to provide

physicians with a valuable tool to predict those patient candidates best suited

to benefit from treatment with SinuNase - a comprehensive approach to diagnosis

and treatment.

BiovaxID Through our majority-owned subsidiary, Biovest International,

Inc. (OTCBB:BVTI), we are extremely optimistic and excited regarding the

progress of BiovaxID, a personalized cancer vaccine, now in a pivotal Phase 3

Fast-Tracked trial, that is initially targeting non-Hodgkin s lymphoma, with the

potential to treat many difficult-to-treat B-cell related cancers such as

multiple myeloma and chronic lymphocytic leukemia.

BiovaxID is nearing the completion of an interim analysis for BiovaxID,

and we expect to report the analysis of the unblinded results by the end of

April 2008.

Based on very favorable follow-up data from previous Phase 2 studies

reported by the National Cancer Institute and independent research conducted in

Spain, coupled with statistical evidence from blinded data suggesting that

BiovaxID is achieving efficacy endpoints with an excellent overall safety

profile, we remain confident that we will report statistically significant

survival benefits; such positive results would allow us to move forward in

seeking accelerated and conditional approvals in the U.S.

and Europe later this year.

Pending Milestones for BiovaxID in 2008: -- Report results from the

unblinding and complete analysis of the pivotal Phase III clinical trial by the

end of April 2008 -- Meet with the FDA to present data and determine

registration pathways for accelerated approval in the U.S.by mid-calendar year

2008 -- Meet with the EMEA to present data and determine expedited registration

pathways for conditional approval in EU by mid-calendar year 2008 -- Launch

marketing and sales initiatives upon conditional approval -- Announce strategic,

multi-national, marketing partnership BiovaxID is a customized therapy, unique

from any other cancer vaccine, in the manner in which it is derived from a

patient s own cancer cells; designed to harness the power of the patient s

immune system, by " training " it to recognize and selectively destroy just

cancerous lymphoma cells.

http://www.infobolsa.es:80/v2002/Noticias/noticias_titulares2.asp?Fuente=IBNW & Fe\

chaNot=20080107 & Clasif=C & Numnot=104952